Pharmaceuticals

Drugs for Immunotherapy Market Outlook 2026–2030: Key Business Drivers and Trends

February 13, 2026February 13, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the drugs for immunotherapy market from 2026–2035 with trusted insights from The Business Research Company

What is the expected shift in the Drugs for Immunotherapy Market’s size between 2026 and 2030?

The drugs for immunotherapy market has demonstrated rapid expansion in recent years. It is anticipated to increase from $310.48 billion in 2025 to $349.53 billion in 2026, at a compound annual growth rate (CAGR) of 12.6%. The market’s historic growth can be attributed to several factors, including the availability of limited immunotherapy options, reliance on conventional cancer treatments, an increasing incidence of cancer and autoimmune diseases, a rise in clinical trials for monoclonal antibodies, and developing healthcare infrastructure.

The drugs for immunotherapy market size is projected to undergo rapid expansion in the coming years, reaching $570 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 13.0%. This growth during the forecast period is attributable to advancements in bispecific and conjugated antibodies, the broader application of personalized immunotherapy, increased adoption of checkpoint inhibitors, greater investments in therapeutic vaccine research, and the integration of digital patient monitoring along with AI-guided immunotherapy. Major trends anticipated during this period include the rising acceptance of monoclonal antibodies and checkpoint inhibitors, an increase in treatments for cancer immunotherapy and autoimmune diseases, an escalation in the development of therapeutic and preventive vaccines, the expansion of T-cell receptor and cytokine-based therapies, and the incorporation of immunotherapy into both ambulatory and hospital-based care settings.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2559&type=smp

Which Drivers Are Shaping Strategic Decisions In The Drugs for Immunotherapy Market?

The projected increase in healthcare expenditure is set to boost the expansion of the drugs for immunotherapy market moving forward. Healthcare expenditure is defined as the aggregate sum of money allocated to healthcare goods and services within a specific area or country over a particular period, covering expenses like doctor visits, hospital stays, surgeries, diagnostic procedures, and various treatments. These financial resources, representing health care expenditure, are distributed by individuals, healthcare providers, insurance companies, and government bodies to cover the costs associated with drugs for immunotherapy and other treatments. For instance, in December 2024, figures from the Centers for Medicare & Medicaid Services, a US-based agency tasked with administering the Medicare and Medicaid programs, showed that in 2023, U.S. health care expenditures grew by 7.5%, amounting to $4.9 trillion, or roughly $14,570 for each individual. Therefore, the rise in healthcare expenditure is stimulating the growth of the drugs for immunotherapy market.

What Segment Classifications Make Up The Drugs for Immunotherapy Market?

The drugs for immunotherapy market covered in this report is segmented –

1) By Type: Monoclonal Antibodies, Interferons, Interleukins, Vaccines, Checkpoint Inhibitors, Other Types

2) By Therapy Area: Cancer, Autoimmune & Inflammatory Diseases, Infectious Diseases, Other Therapy Areas

3) By End User: Hospitals & Clinics, Ambulatory Surgical Centers, Other End Users

Subsegments:

1) By Monoclonal Antibodies: Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bispecific Monoclonal Antibodies

2) By Interferons: Interferon Alfa, Interferon Beta, Interferon Gamma

3) By Interleukins: Interleukin-2 (IL-2), Interleukin-6 (IL-6), Interleukin-12 (IL-12)

4) By Vaccines: Preventive Vaccines, Therapeutic Vaccines

5) By Checkpoint Inhibitors: PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4 Inhibitors

6) By Other Types: Cancer Cell Therapies, Cytokine Therapy, T-Cell Receptor Therapy

Which Trends Are Influencing The Performance And Direction Of The Drugs for Immunotherapy Market?

Leading companies within the drugs for immunotherapy market are prioritizing the development of novel offerings, such as Keytruda (pembrolizumab), to deliver effective solutions to consumers. Keytruda (pembrolizumab) functions as an immune checkpoint inhibitor, serving as a targeted immunotherapy drug designed for adult individuals. As an illustration, January 2023 saw the introduction of Keytruda (pembrolizumab) by Merck & Co., Inc., a US-based pharmaceutical firm, following its approval by the Food and Drug Administration, a federal agency also based in the US. This immunotherapy, Keytruda (pembrolizumab), is utilized in combating diverse cancer forms by collaborating with the body’s immune system to target malignant cells. Specifically, KEYTRUDA (pembrolizumab) has received approval for use as an adjuvant therapy in cases of non-small cell lung cancer (NSCLC). Such an advancement marks a considerable milestone in oncology and is projected to bring beneficial effects across the healthcare sector.

Which Major Industry Participants Are Leading The Drugs for Immunotherapy Market Growth?

Major companies operating in the drugs for immunotherapy market are F. Hoffmann-La Roche Ltd., Novartis AG, Merck & Co. Inc., UbiVac, Bayer AG, Celgene Corporation, Incyte Corporation, Juno Therapeutics Inc., Bluebird bio, Celldex Therapeutics, BeiGene, BioNTech AG, CytomX Therapeutics, Eisai Co. Ltd., Flexus Biosciences Inc., Genscript Biotech Corporation, Harpoon Therapeutics Inc., Heptares Therapeutics Ltd., Ignyta Inc., Immatics Biotechnologies, Jounce Therapeutics Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/drugs-for-immunotherapy-global-market-report

Which Region Is Expected To Experience The Fastest Growth In The Drugs for Immunotherapy Market?

North America was the largest region in the immunotherapy market in 2025. Middle East is expected to be the fastest growing region in the drug for immunotherapy market report during the forecast period. The regions covered in the drugs for immunotherapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Drugs for Immunotherapy Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=2559&type=smp

Browse Through More Reports Similar to the Global Drugs for Immunotherapy Market 2026, By The Business Research Company

Immunosuppressant Market Report 2026

https://www.thebusinessresearchcompany.com/report/immunosuppressant-global-market-report

Immunoglobulins Market Report 2026

https://www.thebusinessresearchcompany.com/report/immunoglobulins-global-market-report

Immunofluorescence Assay Market Report 2026

https://www.thebusinessresearchcompany.com/report/immunofluorescence-assay-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795